I guess the good news is that we caught up to Qsymia in less then half the time, when you consider every 2 scripts represent a single patient.
Live feed link go to time stamp I listed above.
finance.senate dot g*v/hearings/hearing/?id=d07b4651-5056-a032-5283-5915780f0ccf
Offered and withdrawn, with 2 comments.... I posted the time stamp on the live feed. 05:01:40.... So it is not being voted on today at all, but by offering it up and withdrawing it others are now free to get on board and debate it merits of it... At least the ball is rolling but we have a long way to go.
Call option volume is not that big when you consider the pop we have had today. What volume are you looking at? Maybe 3300 contracts across all of the options months and strikes for the whole day so far.
IMS subscription service makes the script data available at 12:00 pm EST pon Fridays.... You can pay a little more to get a little jump on them....
IMS will release on Bloomberg as usual unless they have a glitch or have some reporting issues. I am sure if it is real good, we won't get tweets or posts on it right off the bat... or at least that seems to be the pattern..
Makes a person feel all warm and fuzzy when a big firm like Oppenheimer lays out almost 40 million dollars on the same investment you got into. They did not buy it as indexing they are investing in the world wide potential of Belviq..... Great Post S9
Yes provided that bill does not have so many attachments that it then becomes disliked because of pork and other special interest deals.
Thanks Sharon, I guess it is not updated on the site yet. Great catch... Treating obesity before it becomes diabetes or other expensive life threatening disease is very important and will save the tax payers 100's of billions of dollars.
I don't see that change on the bill tracking web site...
.govtrack dot us/congress/bills/113/hr2415
IF the Senate or the House make a positive move on the Treat and Reduce Obesity Act, that would be catalyst that many of us were not counting on. Don't have to pass it but having bipartisan support would send a very loud message. Coverage is going to be way ahead of schedule...
Nov. 13 CC.
So what we added on top of the milestones were: #1, the SURFAXIN launch. SURFAXIN is now cleared by the FDA. And just this past week, we announced that we launched SURFAXIN. And during the Q&A period of this call, we intend to get into more details with you. But most importantly, it's been a long road. It's been a -- I think the road right now where we are looking forward. We're not looking back.